Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Louise Elkjær Fløe; Inge Marie Svane; Lars Bastholt; Henrik Schmidt

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Translated title of the contribution: Immune checkpoint antibodies increase survival in patients with metastatic melanoma

Louise Elkjær Fløe, Inge Marie Svane, Lars Bastholt, Henrik Schmidt

2 Citations (Scopus)

Abstract

The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

Translated title of the contribution	Immune checkpoint antibodies increase survival in patients with metastatic melanoma
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	178
Issue number	33
ISSN	0041-5782
Publication status	Published - 15 Aug 2016

Keywords

English Abstract
Journal Article

Cite this

@article{e81763228b30472aa2a702a54bfdcd9e,

title = "Immuncheckpointantistoffer {\o}ger overlevelsen for patienter med metastatisk melanom",

abstract = "The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.",

keywords = "English Abstract, Journal Article",

author = "Fl{\o}e, \{Louise Elkj{\ae}r\} and Svane, \{Inge Marie\} and Lars Bastholt and Henrik Schmidt",

year = "2016",

month = aug,

day = "15",

language = "Dansk",

volume = "178",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "33",

}

TY - JOUR

T1 - Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

AU - Fløe, Louise Elkjær

AU - Svane, Inge Marie

AU - Bastholt, Lars

AU - Schmidt, Henrik

PY - 2016/8/15

Y1 - 2016/8/15

N2 - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

AB - The incidence of melanoma is rising and until recently, metastatic melanoma had a poor survival prognosis. Manipulation of two newly discovered immune pathways have shown impressive results. The first is treatment with anti-cytotoxic T-lymphocyte-antigen (CTLA)-4 antibody which blocks the inhibitory receptor CTLA-4. The other is anti-programmed cell death (PD)-1 antibody which blocks the inhibitory receptor PD-1 on T-cells. Thereby, the T-cells are kept activated and able to attack cancer cells.

KW - English Abstract

KW - Journal Article

UR - https://www.scopus.com/pages/publications/85030658703

M3 - Tidsskriftartikel

C2 - 27550784

SN - 0041-5782

VL - 178

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 33

ER -

Immuncheckpointantistoffer øger overlevelsen for patienter med metastatisk melanom

Abstract

Keywords

Other files and links

Fingerprint

Cite this